Regulatory Hurdles Force Boston Scientific to Opt for Minority Stake in M.I. Tech
Portfolio Pulse from Vandana Singh
Boston Scientific Corporation (NYSE:BSX) has terminated its $230 million plan to acquire a majority stake in M.I. Tech, a Korean medical device manufacturer, due to regulatory hurdles. Instead, the company will purchase a minority stake of around 10% later this year.
May 25, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Boston Scientific's plan to acquire a majority stake in M.I. Tech has been terminated due to regulatory hurdles, and the company will now purchase a 10% minority stake.
The termination of the $230 million acquisition plan due to regulatory hurdles is a negative development for Boston Scientific. The company will now only be able to purchase a 10% minority stake in M.I. Tech, which may limit its influence and potential benefits from the partnership. This could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100